Dyadic International (DYAI) Lytham Partners Spring 2026 Investor Conference summary

Strategic transition and commercial progress

• Transitioned from R&D to commercial stage, launching six products in the past year across life sciences, food nutrition, and bioindustrial markets.

• Diversified revenue model includes product sales, licensing, profit sharing, and partnerships, with initial purchase orders received in all segments.

• Strong balance sheet and disciplined operating structure support expansion and growth.

• Global distribution agreements and recurring revenue streams are in place, with early commercial traction and bulk orders.

• Partnerships with major players like Proliant, IBT, Fermbox, and Inzymes drive product launches and market reach.

Technology and market positioning

• Proprietary C1 and Dapibus platforms enable efficient, scalable production of high-value proteins for diverse applications.

• Focus on non-animal, sustainable protein production aligns with growing market and regulatory demand for ethical, pure proteins.

• Precision fermentation technology underpins competitive advantage in quality, scalability, and cost.

• Targeting large, growing end markets in life sciences, food nutrition, and bioindustrial sectors.

• Early revenues concentrated in food and nutrition, with expansion planned into GMP and clinical-grade segments.

Revenue generation and partnership models

• Revenue streams include direct product sales, OEM/white label, licensing, and profit-sharing arrangements.

• Notable licensing deal with Proliant for AlbuFree DX and profit-sharing with Fermbox and Inzymes.

• Co-manufacturing and co-promotion of DNase I and other enzymes with partners, with first bulk orders received.

• Partner-driven approach in food and nutrition to remain capital light and leverage market expertise.

• Upfront milestone fees of nearly $3.5 million received from Proliant and Inzymes for developed strains.